Mark E. Robson
Impact in
- Genetics top 0.05%
- BRCA gene mutations in cancer
- Genetic Associations and Epidemiology
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
Papers in
- Genetics 271
- BRCA gene mutations in cancer 250
- Genetic Associations and Epidemiology 18
-
- Breast Cancer Treatment Studies 42
- Cancer Genomics and Diagnostics 22
- Co-authors
- Kenneth Offit (76 shared papers)Susan M. Domchek (37 shared papers)Jaya M. Satagopan (12 shared papers)Nadine Tung (17 shared papers)Larry Norton (35 shared papers)Jeff A. Boyd (18 shared papers)Elżbieta Senkus (11 shared papers)Seock‐Ah Im (11 shared papers)
- Journals
- Journal of Clinical Oncology (36 papers)Breast Cancer Research and Treatment (24 papers)Annals of Oncology (22 papers)JCO Precision Oncology (19 papers)JNCI Journal of the National Cancer Institute (18 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Mark E. Robson
448 papers receiving 44.1k citations
Mark E. Robson's Hit Papers
Peers
Comparison fields: 5 of 181
- Genetics 17.8k
- Cancer Research 7.6k
- Oncology 8.7k
- Pulmonary and Respiratory Medicine 6.3k
- Reproductive Medicine 1.4k
Countries citing papers authored by Mark E. Robson
This map shows the geographic impact of Mark E. Robson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Robson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Robson more than expected).
Fields of papers citing papers by Mark E. Robson
This network shows the impact of papers produced by Mark E. Robson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Robson. The network helps show where Mark E. Robson may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark E. Robson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 460 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Hit paper breakdown → | 2017 | 2685 |
| 2 | Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation Hit paper breakdown → | 2017 | 2591 |
| 3 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1453 |
| 4 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer Hit paper breakdown → | 2016 | 1344 |
| 5 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Hit paper breakdown → | 2021 | 1015 |
| 6 | Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation Hit paper breakdown → | 2002 | 1014 |
| 7 | Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group Hit paper breakdown → | 2020 | 890 |
| 8 | The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers Hit paper breakdown → | 2018 | 776 |
| 9 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes Hit paper breakdown → | 2018 | 775 |
| 10 | Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk Hit paper breakdown → | 2015 | 739 |
| 11 | Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes Hit paper breakdown → | 2017 | 679 |
| 12 | 2004 | 611 | |
| 13 | OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer Hit paper breakdown → | 2019 | 601 |
| 14 | High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants Hit paper breakdown → | 2019 | 589 |
| 15 | American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility Hit paper breakdown → | 2015 | 588 |
| 16 | Cancer therapy shapes the fitness landscape of clonal hematopoiesis Hit paper breakdown → | 2020 | 559 |
| 17 | Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1 / 2 (CIMBA) Hit paper breakdown → | 2012 | 538 |
| 18 | Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer Hit paper breakdown → | 2018 | 489 |
| 19 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer Hit paper breakdown → | 2013 | 468 |
| 20 | Genome doubling shapes the evolution and prognosis of advanced cancers Hit paper breakdown → | 2018 | 459 |
About Mark E. Robson
Mark E. Robson is a scholar working on Genetics, Cancer Research, Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 460 papers that have together received 45.2k indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (250 papers), Breast Cancer Treatment Studies (42 papers), PARP inhibition in cancer therapy (37 papers), Cancer Genomics and Diagnostics (22 papers), Genetic Associations and Epidemiology (18 papers), Genetic factors in colorectal cancer (13 papers), Forest Management and Policy (10 papers) and Advanced Breast Cancer Therapies (10 papers). The work is most often cited by research in Genetics (17.8k citations), Cancer Research (7.6k citations), Oncology (8.7k citations), Pulmonary and Respiratory Medicine (6.3k citations) and Reproductive Medicine (1.4k citations). Mark E. Robson has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Kenneth Offit, Susan M. Domchek, Jaya M. Satagopan, Nadine Tung, Larry Norton, Jeff A. Boyd, Elżbieta Senkus, Seock‐Ah Im, Norikazu Masuda and Binghe Xu. Their work appears in journals such as Journal of Clinical Oncology, Breast Cancer Research and Treatment, Annals of Oncology, JCO Precision Oncology and JNCI Journal of the National Cancer Institute.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.